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Finding a Link Between the TRPV4 Ion Channel and Angiogenesis: A potential 
Therapeutic Target for Ischemic Heart Disease 
 
Vanessa Salucci  
 
 
Angiogenesis is the physiological process of creating new blood vessels. It is the body’s natural 
healing response to restore blood flow to damaged tissue. For people dealing with chronic 
diseases such as ischemic heart disease, the angiogenic response can be compromised. Calcium 
ions play an important role in several cellular processes, including cell proliferation. Transient 
Receptor Potential cation channel subfamily Vanilloid member 4 (TRPV4) is moderately 
permeable to Ca2+ and can be found in endothelial cells, which make up the inner lining of blood 
vessels. This study investigates the link between the TRPV4 channel and angiogenesis using an 
Aortic Ring Assay (ARA) on a mouse model. By exposing the rings to specific ion channel 
agonist (GSK1016790) and antagonist (HC067047), measurements of length and number of new 
blood vessel outgrowth were taken. Significant findings from this study can provide pertinent 
information on TRPV4 playing an important role as a mediator for intracellular signaling and can 
potentially be a therapeutic target for vascular remodeling to improve cardiac function and 
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Angiogenesis is the process of creating new blood vessels (Nicosia, 2009). It is a normal 
and critical process for the growth and development of the body. Vessels are responsible for the 
transfer of oxygenated blood and nutrients to the cells and the removal of metabolic waste and 
carbon dioxide from the cells (Vriens et al., 2004). There are two primary mechanisms by which 
angiogenesis occurs. The first is sprouting, which is the mechanism of interest for the purpose of 
our research. The second is intussusception, also known as splitting angiogenesis; this method 
uses an existing blood vessel that will eventually split into two new vessels (Ribatti et al., 2012; 
Vriens et al., 2004). 
Sprouting occurs in many well-defined phases. As depicted in figure 1, endothelial cells 
need to break through the basement membrane of a preexisting vessel, proliferate, migrate and 
come together to form a new blood vessel (Spin et al., 2004; Vriens et al., 2004). For this to 
begin, biological signals, call upon angiogenic growth factors that need to activate receptors on 
the endothelial cells found in preexisting blood vessels. Pro-angiogenic factors are produced 
while anti-angiogenic factors are decreased by mechanisms such as high blood glucose, shear 
force, hypoxia or metabolic stress (Vriens et al., 2004; Zent and Pozzi, 2007). The combination 
of these factors is what initiates angiogenesis.  
Once the cells are activated, they release enzymes called proteases; their purpose is to 
degrade the basement membrane to allow endothelial cells to escape their vessel of origin 
(Ribatti et al., 2012). The breakdown causes perivascular cells (pericytes and smooth muscle 
cells) to detach from escaped endothelial cells (Thibeault et al., 2008). When the cells are 
released, they proliferate into the surrounding matrix and form sprouts. While extending toward 
the source of the stimulus, the cells migrate collectively using adhesion molecules called 
integrins. As they mature, the sprouts eventually form a loop to create the vessel lumen (Spin et 







Angiogenesis as a therapeutic target   
 
Angiogenesis is controlled by the production of a precise balance of growth and 
inhibitory factors in healthy tissue. This process is the body’s natural healing response to restore 
blood flow to the damaged tissue. To initiate activity, various chemical signals such as growth 
factors, inflammatory and immune proteins are released into the tissue in need and are 
responsible for stimulating angiogenesis.  When this balance is disturbed, the result is either too 
much or too little angiogenesis, which can lead to important and sometimes fatal conditions 
(Masson et al., 2002). For people dealing with chronic diseases, the angiogenic response can be 
compromised for different reasons. Diabetes for example, can cause many secondary conditions 
such as foot ulcers and nerve damage; they are the result of insufficient angiogenesis (Vriens et 
al., 2004). Angiogenesis may be a target for therapies dealing with such diseases. Applying 
specific agents that inhibit or stimulate the creation of new blood vessels in the body may assist 
in the prevention or control of these diseases. 
The absence of blood vessels in a metabolically active tissue may inhibit essential 
functions. Many diseases, such as ischemic heart disease (IHD) or coronary heart disease, are the 
result of a lack of sufficient blood vessel formation and thus an insufficient blood supply to the 
area that can lead to tissue death (Stegmann et al., 1998; Stegmann et al., 2000; Folkman, 1998). 
Figure 1: Stages of Angiogenesis The red cells represent endothelial cells while the blue ones are 
perivascular cells. In the early stages, there is a degradation of the basement membrane (1). The 
endothelial cells then begin to migrate and begin to form sprouts (2). They then further elongate via 
endothelial cell proliferation and branch out (3). Lastly the mature sprouts recruit the perivascular cells 
to support and stabilize the vessel (Laschke et al., 2011). 
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Pro-angiogenic therapies are being investigated as an option to treat and prevent cardiovascular 
disease, the primary cause of death in the world (World Health Organization, 2013). These 
studies include using fibroblast growth factor 1 (FGF-1) for the treatment of coronary heart 
disease (Stegmann et al., 1998; Stegmann et al., 2000; Folkman, 1998). Also, many studies have 
looked at vascular endothelial growth factor (VEGF) (Nicosia, 2009; Ribatti et al., 2012). 
Angiogenesis is an excellent potential therapeutic target for the treatment of 
cardiovascular disease. It is an effective, physiological process that triggers the natural way our 
bodies respond to a decreased blood supply to a vital organ. It may even help regenerate 
damaged tissue in ways that were previously considered impossible (Spin et al., 2004; 
Woudenberg-Vrenken et al., 2009).  
 
Transient Receptor Potential (TRP) 
 
The transient receptor potential (TRP) superfamily consists of numerous cation channels 
that are expressed in the majority of tissues and cell types. They can be found in the neuronal, 
renal and smooth muscle tissue among others, thus playing an important role in the regulation of 
these different cells. There are 28 mammalian TRP channels that can be divided into six 
subfamilies: the TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPP (polycystic), 
TRPML (mucolipin) and TRPA (ankyrin) groups (Dietrich et al., 2006; Nilius et al., 2007). 
All TRP channels are composed of 6 transmembrane domains, which present themselves 
in tetramers to form the pore responsible for cation entry into the cell. In these structures, it is the 
fifth and sixth transmembrane domains from each unit that form this pore and the sixth domain 
actually controls the intracellular gating, as seen in figure 3  (Clapham, 2003; Dietrich et al., 
2006; Nilius et al., 2013). Once the opening is formed, it allows cations such as Ca2+ into the 
















Figure 2: TRP Cation Channel Structure A schematic depiction of TRP cation channel structure to show all 6 
transmembrane domains (A), and in tetrameric formation to show the cation pore (B) (Adapted from Berridge et al., 
2000).    
 
Most TRP channels are permeable to Ca2+, however other ions such as Na+ undergo 
cellular influx as well (Berridge et al., 2000; Christensen and Correy, 2007). The majority of 
these channels are poorly selective for calcium ions, with permeability ratio (PCa/PNa) in the 
range of 0.3 to 10. TRP channels are gated by different stimuli that include intracellular and 
extracellular messenger binding, temperature changes, chemical or mechanical stress (Nilius et 
al., 2007).  
Several of these channels are involved in the control of cell proliferation and maturation. 
Alterations in this function may lead to growth disruptions. Disturbances in physiological 
functions controlled by ion channels can contribute to the start of certain diseases. Changes in the 
number of channels activated or channel sensitization will result in exaggerated or decreased 
responses to stimuli. Many members of the TRP superfamily are prone to being targets for these 
factors. They are mostly polymodal meaning they are activated by many different types of gating 
stimuli and act like mediators for internal and/or external signals. Abnormal regulation of these 
(!
ion channel functions can be linked to many forms of inflammation and systemic diseases, such 
as neurodegenerative, cardiovascular and respiratory diseases (Nilius et al., 2007).   
Unfortunately, the mechanisms of TRP channel functions are not completely understood 
yet. Many mechanisms have been suggested for the dysregulation of TRP channel function 
leading to disease. One of the mechanisms states that, since most TRP channels play a role in 
Ca2+ signaling, changes in signaling due to disrupted TRP channel function can have severe 
effects on many cellular and systemic processes (Nilius et al., 2007).   
 
Transient Receptor Potential Cation Channel, Vanilloid subfamily Member 4 (TRPV4)  
 
 The TRPV (vanilloid) subfamily is comprised of six members (TRPV1-6). TRPV1-
TRPV4 channels are all heat-activated channels that are nonselective for cations and modestly 
permeable to Ca2+ (Vriens, 2004). The channel of interest for the purpose of our research is the 
non-selective cation channel, TRPV4. It is an important factor in many physical and chemical 
stimuli and is involved in multiple physiological functions (Verma et al., 2010). This specific 
channel is activated in the presence of cell swelling, moderate heat, shear stress and many 
protein kinase enzymes (Nilius et al., 2007; Plant et al., 2007). Although it allows both calcium 
and sodium cations into the cell, it has a PCa/PNa equal to 6. This means that it is six times more 
selective to Ca2+ than Na+ (Christensen et al., 2007; Clapham, 2003; Dietrich et al., 2006).    
 There are other ways to activate TRPV4 such as agonistic compounds (Berridge et al., 
2000; Christensen et al., 2007; Nilius et al., 2007; Swapnil et al., 2012). Among these activating 
compounds, GSK1016790A is considered one of the strongest and most specific agonists (Jin et 
al., 2011; Rerup et al., 1970; Schnedl et al., 1994).    
Calcium signaling and endothelial cell proliferation !
Calcium ions play an important role in several cellular processes, which include muscle 
contraction, cell proliferation, gene transcription and cell death (Berridge et al., 2000). Under 
normal circumstances, proliferation of capillary endothelial cells is particularly limited within an 
adult, taking into consideration their 1000-day half-life (Engerman et al., 1967). However 
proliferation is triggered if the cells are exposed to angiogenic stimuli (Haas et al., 2012).  
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Resting Ca2+ concentration in the cytoplasm can be found anywhere between 10 and 
100nM. To maintain this constant concentration, Ca2+ is pumped into the extracellular area and 
in the endoplasmic reticulum (ER) (Clapham, 2007). TRP channels contribute to changes in the 
cytosolic free-Ca2+ concentration. They do so by either acting as calcium ion entry pathways or 
via changes in membrane polarization, ultimately modifying the driving force for calcium ion 
entry mediated by alternative pathways (Garcia-Elias et al., 2008; Nilius et al., 2007; Strotmann 
et al., 2003). This means that intracellular Ca2+ increases in endothelial cells due to Ca2+ influx, 
but can also arise from Ca2+ release from internal calcium ion stores such as the Golgi apparatus, 
the endoplasmic reticulum (ER), or in the case of muscle cells, the sarcoplasmic reticulum (SR) 
(Nilius et al., 2007). In the case of members of the TRP family, concentrations of intracellular 
Ca2+ are increased by influx and by release from intra-cellular stores in the ER (Swapnil et al., 
2012).  
 
Figure 2: Cellular Ca2+ Signaling Specific channels mediate Ca2+ signaling through certain pathways. These 




Inositol triphosphate (IP3) and Calmodulin (CaM) are two proteins that have been found 
to interact with TRPV4, serving as messengers (Verma et al., 2010). In figure 2, we can see that 
CaM is bound to the channel (represented in red) and is activated by the Ca2+ influx. The ions 
then travel across the plasma membrane and form intracellular Ca2+ stores. The accumulation of 
calcium ions in the cytosol is quickly buffered into microdomains: calcium reservoirs, which can 
be found close to the opening of the channels (Senatore et al., 2009). IP3 on the other hand, will 
bind to ligand-gated Ca2+ channels found on the surface of the ER and trigger the release of Ca2+ 
into the cytoplasm, increasing the intracellular Ca2+ concentration (Clapham, 2007). These 
mechanisms are what trigger transcriptional factors through various pathways, which bring on 
the start of endothelial cell proliferation.  
!Aortic Ring Assay  
 
 The study of angiogenesis as a therapeutic target is highly present in the literature. 
Scientists are using various methods to elicit and control the growth of the new blood vessels and 
determine the mechanisms involving angiogenic growth. Few however, have addressed the link 
between TRPV4 channel and angiogenesis. In an attempt to find the potential link between these 
two, we will be employing the aortic ring assay (ARA) from a mouse model. Originally based on 
the rat aorta, this method has been used to study angiogenic growth since its initial development 
in 1990, by Nicosia and Ottinetti (Nicosia and Ottinetti, 1990). Since then, it has become one of 
the leading assays for angiogenesis simulation (Aplin et al., 2008; Masson et al., 2002; Nicosia, 
2009).  
 The ARA is an organ culture model where vessels grow from a segment of an aorta. In 
this kind of assay, the thoracic aorta is removed from the mouse, the adventitia is cleared away 
and the segment is cut into approximately 1mm rings, which are then embedded into a collagen 
gel (Nicosia and Ottinetti, 1990). The rings are then ready to be cultured in a serum-free 
medium. In our case, we will also be adding the specific ion channel agonist (GSK1016790A) 
and antagonist (HC067047) to certain rings. The angiogenic growth can be seen quite rapidly, 
after 2-3 days of culture (Nicosia, 2009), through microscopy (Goodwin, 2007).  
 The vessels that grow from the aortic rings are anatomically similar to new agiogenic 
growth that can be observed in vivo, meaning that they recruit smooth muscle cells and pericytes 
to come together with the endothelial cell tube (Nicosia et al., 1992; Nicosia and Villaschi, 
,!
1995). There are many limitations, however, to this assay. The handling of the rings and the 
removal of adventitia can greatly vary depending of the laboratory technician and can influence 
vessel growth. The use of different aortas from different mice, different ages and strain can lead 
to variability when measuring angiogenic growth (Zhu et al., 2003). Also, vessel outgrowth 
normally occurs in three dimensions, this can complicate photography and quantification of the 
sprouts. Neovessels usually grow from microvessels such as capillaries, not from the aorta, 
which is a major vessel. However, for the purpose of our study, the aorta will be the vessel of 
choice. It is the only artery large enough to use from a mouse approximately 4 days old. Another 
limitation would be the fact that when compared with in vivo models, an ARA lacks blood flow. 
This drawback is shared with other methods such as in vitro and ex vivo models of angiogenesis. 
As a consequence, the ARA model lacks haemodynamic factors and mechanochemical forces 
that therefore cannot be studied in this particular environment (Shiu et al., 2005). When all 
factors are taken into consideration, with enough internal control and with multiple repeats, this 
assay is fairly simple, inexpensive, reproducible, greatly correlates with in vivo studies, highly 
informative and significantly superior when compared to endothelial cultures in terms of its 
relevance and biological complexity (Bellacen and Lewis, 2009; Nicosia, 2009).    
Objectives and Rationale 
 
Objective 1  
 By applying the aortic ring assay method, we determined the effect and degree that the 
specific ion channel agonist (GSK10161790A) has on TRPV4, when it comes to lengthening and 
multiplying new sprouts during angiogenesis.  
 
Objective 2 
By applying the aortic ring assay method, we determined the effect and degree that the 




Insufficient amounts of blood vessels contribute to the start of many diseases. Stimulating 
angiogenesis can improve and increase blood flow in patients with ischemic diseases (Goodwin, 
-!
2007). Pro-angiogenic agents have been used to treat diseases like peripheral vascular disease 
and coronary artery disease, however many of their mechanisms are unknown (Khan et al., 2003; 
Zhou et al., 2007).    
The influx of calcium ions via the TRPV4 ion channel is important for cellular 
homeostasis seeing as how it maintains basal Ca2+ concentrations and allows Ca2+ dependent 
events to occur, such as signaling (Clapham et al., 2003; Dietrich et al., 2006; Nilius and 
Owsianik, 2010). Since TRPV4 can be found in many different types of tissue such as 
endothelial cells, smooth muscle cells, the bladder, the brain, the kidney, neurons and cartilage 
(Dietrich et al., 2006; Nilius et al., 2007), maintaining homeostasis through the TRPV4 ion 
channel may have a great impact.    
Exposing the surface of endothelial cells to the selective TRPV4 channel agonist 
GSK1016790A (GSK; 10nM) prompted an increase in Ca2+ signals [30.4 ±2.5 (SEM) –fold, 
n=5], creating an increase in calcium ion influx and stimulated intracellular receptor activity 
responsible for calcium signaling (Swapnil et al., 2012). It is 300 fold more potent than 4!-PDD, 
a strong TRPV4 agonist. As for HC067047, it is a potent and highly selective TRPV4 antagonist 
(Sigma-Aldrich, 2014). It has been shown to reduce the number of active sites, as well as the 
activity per site (Swapnil et al., 2012). In our study, we will be using the TRPV4 channel to 
determine if its effect on cellular homeostasis and proliferation will influence angiogenesis.  
Hypotheses  
 
! We hypothesized that when the TRPV4 agonist, GSK10161790A, and growth media are 
introduced to an aortic ring of a mouse while performing an ARA, the ion channel will 
increase angiogenic activity by increasing the length and number of sprouts when 
compared to an aortic ring that is introduced solely to growth medium.  
 
! We hypothesized that when the TRPV4 antagonist, HC067047, and growth media are 
introduced to an aortic ring of a mouse while performing an ARA, the ion channel will 
decrease angiogenic activity by decreasing the length and number of sprouts when 
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Angiogenesis is the physiological process of creating new blood vessels. It is the body’s natural 
healing response to restore blood flow to damaged tissue. In the case of ischemic heart disease, 
the angiogenic response can be compromised. Calcium ions play an important role in several 
cellular processes, including cell proliferation and gene transcription. Transient Receptor 
Potential cation channel subfamily Vanilloid member 4 (TRPV4) is moderately permeable to 
Ca2+ and can be found in endothelial cells, which make up the inner lining of blood vessels. This 
study investigated the potential link between the TRPV4 channel and angiogenesis using an 
Aortic Ring Assay (ARA) on a mouse model. 4-day-old C57Bl/6 pups were euthanized prior to 
the removal of the aortas. The vessels were cleaned and cut into ±1mm wide rings and were kept 
viable in a collagen growth matrix. By exposing the rings to specific ion channel agonist 
(GSK1016790) and antagonist (HC067047), we measured the length and number of new sprouts. 
The results revealed a significant decrease in number and length of sprouts when rings were 
exposed to the antagonistic compound. As well as a significant increase in sprout length when 
exposed to the antagonistic compound. This study can provide pertinent information on TRPV4 
playing an important role as a mediator for intracellular signaling and can potentially be a 
therapeutic target for vascular remodeling. 
 












Angiogenesis is the process of creating new blood vessels (Nicosia, 2009). It is a normal 
physiological function and is a critical process for the growth, development and healing process 
of the body. Vessels are responsible for the transfer of oxygenated blood and nutrients to the 
cells and the removal of metabolic waste and carbon dioxide from the cells (Vriens et al., 2004). 
The endothelial cells (EC), which make up the inner lining of blood vessels, are the key players 
in the angiogenic process. In order for sprouting to occur, ECs need to break through the 
basement membrane of a preexisting vessel. They then need to proliferate to provide enough 
cells before they can migrate and come together to form a new blood vessel (Spin et al., 2004; 
Vriens et al., 2004).   
 Calcium ions play an important role in several cellular processes, which include muscle 
contraction, cell proliferation and gene transcription (Berridge et al., 2000). Calcium influx 
through gated calcium channels activates gene transcription. The calcium signaling depends on a 
cascade of events, which ultimately open these calcium channels. The ions are then able to travel 
across the plasma membrane and form intracellular Ca2+ stores through specific receptors. The 
accumulation of calcium ions in the cytosol is quickly buffered into microdomains: calcium 
reservoirs. They are responsible for triggering transcriptional factors through several different 
pathways, which is the start of endothelial cell proliferation (Senatore et al., 2009).   
Transient Receptor Potential Cation Channel, Vanilloid subfamily Member 4 (TRPV4) is 
modestly permeable to Ca2+ (Vriens, 2004). It is an important factor in many physical and 
chemical stimuli and is involved in multiple physiological functions (Verma et al., 2010). This 
specific channel is activated in the presence of cell swelling, moderate heat, shear stress and 
many protein kinase enzymes (Nilius et al., 2007; Plant et al., 2007). Among these activating 
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compounds; GSK1016790A is considered one of the strongest and most specific agonists (Jin et 
al., 2011; Rerup et al., 1970; Schnedl et al., 1994).    
 Originally based on the rat aorta, the aortic ring assay has been used to study angiogenic 
growth since its initial development in 1990, by Nicosia and Ottinetti and has become one of the 
leading assays for angiogenesis simulation (Aplin et al., 2008; Masson et al., 2002; Nicosia, 
2009). The vessels that grow from the aortic rings are anatomically similar to angiogenic growth 
that can be observed in vivo, meaning that they recruit smooth muscle cells and pericytes to 
come together with the endothelial cells to for the tube structure (Nicosia et al., 1992; Nicosia 
and Villaschi, 1995).  
 In an attempt to find the potential link between TRPV4 and angiogenesis, we will be 
employing an aortic ring assay. We hypothesized that TRPV4 agonist GSK1016790A and 
antagonist HC067047 could directly affect the formation of new blood vessels created by 
sprouting angiogenesis. The purpose of this study is to investigate whether these two compounds 
would affect angiogenic growth in terms of number and length of the new microvessels.  
 
Materials and Methods  
Tissue preparation  
 Four-day-old C57BL/6 mice were euthanized by decapitation according to the protocol 
approved by the Animal Ethics Committee of Concordia University (#30000259). Before any 
ventral incisions, the surface was sterilized using 70% ethanol. Once the abdominal cavity was 
exposed, the aortic arch was located and was followed down the anterior of the spine. After 
separating it from the connective tissue, the aorta was placed in iced, sterile Ca2+-free Krebs 
solution containing (in mmol/L) 122 NaCl, 15.5 NaHCO3, 4.7 KCL, 1.2 MgCl2, 1.2 KH2PO4, 1.5 
%+!
glucose, 100 U/mL penicillin, and 100Ig/mL streptomycin. Using a dissection microscope, all 
excess adipose tissue was carefully removed and vessels were cut into ~1mm long rings.  
 
Matrix preparation  
  Gel matrices were prepared under sterile conditions in a biological safety cabinet 
(Lanconco Class II, type A2) by mixing 1.5ml of DMEM:F12 and 30µL rat collagen. Further 
mixtures were made with the TRPV4 channel agonist (GSK1016790A) and antagonist 
(HC067047) each having 2 concentrations of 3 and 10nM, all with 2% collagen concentration. 
Solutions were kept on ice to prevent early polymerization of the collagen.  
 DMEM/F12 contains 0.1545g/L calcium chloride and is frequently used as a base media 
for the development of cells. Calcium is essential for the life of all cells. It acts as an important 
second messenger in the majority of cellular functions (Voccoli et al., 2014). Since calcium 
affects cell signaling and differentiation, media developed for specific cell types may require 
lower calcium levels for cell viability (Huang et al., 2006).  
 
Embedding  
 Mixtures were transferred to a 96-well plate using a 0.45µm syringe. The aortic rings 
were placed in the center of each well with the luminal axis perpendicular to the bottom to 
facilitate sprout visualization. The plate was then placed in an incubator (VWR Symphony) at 37 
°C for about 15 – 20 minutes to accelerate the solidification of the collagen before filling the rest 





 Every second day, the aortic rings were imaged using a Leica inverted microscope (Leica 
DMIRE2) with a 10x objective connected to a camera, for up to 12 days. To maintain 
consistency and allow for accurate quantification and analysis, images were taken at roughly the 
same focal distance. ImageJ software was used to measure maximum sprout length and total 
number of sprouts.  
Statistical Analysis   
 Experiments included a sample size of 12 rings per condition and were conducted on 3 
separate 96-well plates. The number and length of sprouts were determined, as well as growth 
ratios and number of ECs. The following statistical parameters were calculated to describe the 
distribution of microvessels: the mean distribution and standard deviation.  Summarized data are 
presented as mean ± standard error (SEM) in all figures. Statistical comparisons were done using 
an ANOVA test. For all statistical assessments a p value of <0.05 was considered significant.  
 
Results  
In order to avoid masking the angiogenic effects of GSK1016790A and HC067047, 
aortic rings were deprived of all exogenous growth factors during the 12-day, sterile incubation. 
In figure 1A we observed that under control conditions, the aortic ring generated new blood 
vessels and that the density of these vessels increased over time. Fig.1B demonstrates that with 
the addition of 3nM of the agonist, GSK1016790A, the vessels grew at a faster rate and sprouts 
grew longer over time. Conversely, in Fig.1C there is an inversely proportional trend, adding 
3nM of antagonist HC067047 shows a clear reduction in microvessel formation.  
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The number of new sprouts developing from a segment of aortic tissue is a common 
method for measuring angiogenic stimulation or inhibition. As seen in Fig.2, a dose-dependent 
response for both the agonist and antagonist can be seen. We can see that the number of sprouts 
increases as the agonist concentration increases as well as a decrease in number when the 
antagonist concentration increases. The greatest amount of microvessels can be seen at day 10 
for all treatments, right before it slightly decreases at the end of the study.   
The capacity in which a capillary can penetrate into surrounding tissue was also taken 
into consideration. The maximum length of sprouts is depicted in Fig.3.  The longest 
microvessels can be seen in the group containing the highest concentration of the agonistic 
compound (10nM), an average of 1.51 ± 0.059 mm. Meanwhile, the shortest outgrowths can be 
seen in the most concentrated antagonist group (10nM), an average of 0.83 ± 0.05 mm. The 
growth ratio of each compound’s concentration is depicted in Fig.4, where the control condition 
was set at 1. Both agonist groups showed similar trends as of day 6, both revealed at least 20% 
longer microvessels. Looking at the antagonist groups, the higher concentration (10nM) 
indicated a greater decrease in sprout length, at least 20%. In Fig.6, the logarithmic plot of the 
same growth ratios is depicted. This view allows seeing the exponential growth of the vessels. A 
visible difference can be seen between the various compounds and their different concentrations 
at the very beginning. Day 2 shows the largest gap in growth between the agonist and 
antagonists. We can hypothesize that the compounds affect the ECs at the start of the angiogenic 
growth. 
Cell proliferation, which is the first stage of angiogenesis, was measured at the beginning 
of the experiment, at day 2 and 4 (Fig.5). The addition of agonistic and antagonistic compounds 




 The absence of blood vessels in a metabolically active tissue may inhibit essential 
functions. Many diseases, such as ischemic heart disease, are the result of a lack of sufficient 
blood vessel formation and thus an insufficient blood supply to the area that can lead to tissue 
death (Stegmann et al., 1998; Stegmann et al., 2000; Folkman, 1998). Stimulating angiogenesis 
can improve and increase blood flow in patients with such diseases (Goodwin, 2007). Cell 
proliferation is the first step of angiogenesis, in which calcium plays a large role in (Berridge et 
al., 2000). Intracellular Ca2+ increases in endothelial cells due to increased Ca2+ influx but can 
also arise from Ca2+ release from internal calcium ion stores such as the endoplasmic reticulum 
(ER)(Nilius et al., 2007, Swapnil et al., 2012). We are reporting a novel finding in that the 
TRPV4 ion channel can act as a mediator in intracellular signaling and can potentially be a 
therapeutic target for vascular remodeling.  
 The TRPV4 agonist, GSK1016790 is considered one of the strongest and most specific 
agonists (Jin et al., 2011; Rerup et al., 1970; Schnedl et al., 1994). Our results show us that the 
aortic rings treated with 3nM of this agonist do not show a significant increase in the number of 
sprouts grown when compared to the control condition. However, the group treated with 10nM 
demonstrates a significant difference as of day 8. This indicates that the concentration of 
GSK1016790 could perhaps show significance throughout the entire process at an increased 
concentration. As for the antagonist, HC067047, it is a potent and highly selective TRPV4 
antagonist (Sigma-Aldrich, 2014). We can observe significant inversely proportionate 
relationship between its concentration and the number of microvessel outgrowth. This can be 
explained by the inhibition of Ca2+ influx and thus a decrease of intercellular Ca2+.  
&.!
 The degree of capillary penetration into the surrounding tissue is as important as the 
number of sprout growth. In all conditions, the maximum length can be seen at day 10 right 
before a visible regression. The longest vessels are found in the 10nM treatment of agonist 
compound and all values are significant as of day 8. The regression can be explained by a 
cessation of growth after approximately 1 week of sprouting, branching and network formation. 
This occurrence can be seen especially in serum-free collagen gel cultures (Nicosia, 2009). As 
the new vessels are reabsorbed, the gel inside of the lumen and around the aortic ring starts to 
deconstruct, creating the periaortic halo seen in the Fig.1 (day 12) (Zhu et al., 2000).  
 We wanted to investigate what stage of angiogenesis TRPV4 actually influences. Using 
the images taken during the ARA, the ECs present in the images were counted to see if the ion 
channel plays on the proliferation stage. There is no significant difference between the numbers 
of cells of each treatment group which would lead to believe that TRPV4 actually influences the 
sprout formation phase. This assumption is based on the fact that, among the control and agonist 
conditions, the least amount of free ECs can be found in the highest concentration of agonist 
compound (10nM), the same condition with the highest number of sprouts.  
 Our findings indicate that TRPV4 can act as a potential mediator for intracellular 
signaling and can affect angiogenesis. We hypothesize that this channel can used as a potential 
therapeutic target for vascular remodeling to improve cardiac function and increase perfusion to 
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Fig. 1. Aortic rings under control condition (A), agonist [3nM] (B) and antagonist [3nM] (C) at day 2, 6 











































Fig.2. Number of microvessel outgrowths as a function of time for various agonist (GSK1016790A) and 
antagonist (HC067047) concentrations compared with control condition (means ± SE). Significant 
(p<0.05) findings in antagonist group [3nM] and [10nM] and agonist [10nM] only as of day 8 when 
compared to control.       
 
 
Fig.3 Mean maximum length of microvessels for each treatment condition (means ± SE), representing 
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Closing Remarks  
 
 The aim of this thesis was to find a correlation between the activation and inhibition of 
the TRPV4 ion channel and angiogenesis. The development of new blood vessels is primordial 
for the vitality of organisms; vessels allow a transfer of oxygenated blood and nutrients to cells 
and remove metabolic waste and carbon dioxide from the cells and surrounding tissues. 
Stimulating this growth to accelerate the rehabilitation process of a patient who has just suffered 
a myocardial infarction or perhaps try to prevent the ischemia from occurring in the first place 
has significant clinical relevance.  
 Our findings show that the inhibition of the TRPV4 ion channel shows significant 
decrease in the number and length of vessels sprouting from the aortic rings. As for the agonist 
stimulating the ion channel, significant increase in the length of the sprouts can be seen as of day 
8. Increasing the length of the vessels can play an important role in the penetration of 
neighboring tissue. By increasing perfusion to an ischemic region, coronary artery disease 
symptoms can be alleviated and cardiac function can improve.  
Future work should include an in vivo model where the agonist and antagonist 
compounds are given orally to the mice. The rodents should then follow a high intensity, aerobic 
exercise regiment. This type of exercise has been associated with angiogenesis. Capillaries 
deliver oxygen and nutrients to the muscles and angiogenesis allows the growth of this capillary 
bed in order to keep up with the demand of the working muscles (Barry et al., 2004). Also, 
taking into consideration the results found in this study, seeing similar effects translated in 
human ECs would be great for future research dealing with IHD patients.  
 After investigating the change in number and length of the microvessel outgrowths, we 
needed to determine what stage of angiogenesis was being affected. We decided to count the 
amount of ECs directly from the images being captured from the assay. By doing this, results 
from all rings were taken into consideration and no external factors would influence the results. 
The changes in number of ECs present in each condition were not significant. More experiments 
would need to executed with a larger population in order to investigate what phase of 
angiogenesis is most affected by these compounds.  
'.!
This thesis supports our hypothesis; TRPV4 might in fact act as a mediator of 
intracellular signaling for angiogenesis. It can be considered as a target for future research on 










Aplin A.C., et al., The Aortic Ring Model of Angiogenesis. Methods Enzymol. 443:119- 136 
(2008).  
Barry M. et al. What makes vessels grow with exercise training? Journal of Applied Physiology 
97(3):1119-1128 (2004) 
Bellacen K., Lewis E.C. Aortic Ring Assay. JoVE 33 (2009). 
http://jove.com/details.php?id=1564. Retrieved 11 july 2014.  
Berridge M.J. et al. The versatility and universality of Calcium Signaling. Nat Rev Mol Biol 
1:11-21 (2000).  
Christensen, A. P. & Corey, D. P. TRP channels in mechanosensation: direct or indirect 
activation? Nat Rev Neurosci 8:510-521 (2007).  
Clapham, D. E. TRP channels as cellular sensors. Nature 426:517-524 (2003).  
Clapham, D.E. Calcium Signaling. Cell 131(6): 1047-1058.  
Dietrich, A. et al. Cation channels of the transient receptor potential superfamily: Their role in 
physiological and pathophysiological processes of smooth muscle cells. Pharmacol Therapeut 
112, 744-760 (2006).  
Engerman R.L. et al. Cell turnover of capillaries. Lab Invest. 17:738– 743 (1967). Folkman J. 
Angiogenic therapy of the human heart. Circulation 97(7):628-629 (1998).  
Garcia-Elias A. et al. IP3 receptor binds to and sensitizes TRPV4 channel to osmotic stimuli cia 
a calmodulin-binding site. J Biol Chem 283:31284-31288 (2008).  
Goodwin A.M. In Vitro Assays of Angiogenesis for Assessment of Angiogenic and Anti- 
angiogenic Agents. Microvascular Research 74: 172-183 (2007).  
Haas, T. et al. Exercise Training and Peripheral Arterial Disease. NIH-PA 2.4:15-17 (2012).  
Jin M. et al. Determinants of TRPV4 Activity following Selective Activation by Small Molecule 
Agonist GSK1016790A. PLoS ONE 6(2):16713 (2011).  
Khan T.A. et al. Gene Therapy Progress and Prospects: Therapeutic Angiogenesis for Limb and 
Myocardial Ischemia. Gene Ther. 10: 285-291 (2003).  
Lambert, V. Aorta Ring Assay A New Approach of the Molecular Genetics of Angiogenesis. 
Laboratory of Tumor & Development Biology. University of Liège, Mar. 2009.  
Laschke, M. W. et al. Vasculogenesis: A New Piece of the Endometriosis Puzzle. Human 
Reproduction Update, Oxford Journals 17(5):628-36 (2011).  
''!
Masson V. et al. Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of 
Angiogenesis. Biol. Proced. Online 4(1): 24-31 (2002).  
Nicosia R.F., Ottinetti A. Growth of Microvessels in Serum-free Matrix Culture of Rat Aorta. A 
quantitative Assay of Angiogenesis in Vitro. Lab invest 63: 115-122 (1990).  
Nicosia R.F. et al. Large-vessel endothelium switches to a Microvascular Phenotype During 
Angiogenesis in Collagen Gel Culture of Rat Aorta. Atherosclerosis 95: 191-199 (1992).  
Nicosia R.F., Villaschi S. Rat Aortic Smooth Muscle Cells Become Pericytes During 
Angiogenesis in Vitro. Lab Invest 73:658-666 (1995).  
Nicosia R.F. The Aortic Ring Model of Angiogenesis: a Quarter Century of Search and 
Discovery. J. Cell. Mol. Med. 13(10): 4113-4136 (2009).  
Nilius, B. et al. Transient Receptor Potential Channels in Disease. Physiological Reviews 87:165-
217 (2007).  
Nilius, B. & Owsianik, G. Channelopathies converge on TRPV4. Nat Genet 42:98-100 (2010).  
Nilius, B. et al. The Puzzle of TRPV4 channelopathies. EMBO reports 14(2):152-163 (2013).  
Plant, T. et al. TRPV4. Handb Exp Pharmacol 179:189-205 (2007). Rerup, C. C. Drugs 
producing diabetes through damage of the insulin secreting cells.  
Pharmacol Rev 22, 485-518 (1970).  
Ribatti, D. et al. Sprouting angiogenesis, a reappraisal. Developmental Biology 372:157- 165 
(2012).  
Schnedl, W. J. et al. Transport and Cytotoxicity - Specific Enhancement in Glut2- Expressing 
Cells. Diabetes 43:1326-1333 (1994).  
Senatore, A. et al. Calcium Channels: Regulation of Gene Transcription. Encyclopedia of 
Neuroscience 550-554 (2009). Web. Http://link.springer.com. Retrieved 11 September 2014.  
Shiu Y.T. et al. The Role of Mechanical Stresses in Angiogenesis. Crit Rev Biomed Eng 33: 431-
510 (2005).  
Sigma-Aldrich. Product description and properties. Sigma-Aldrich product catalogue (2012). 
Available at http://www.sigmaaldrich.com. Retrieved 10 October 2014.  
Spin, J. M. et al. Transcriptional profiling of in vitro smooth muscle cell differentiation identifies 
specific patterns of gene and pathway activation. Physiol Genomics 19;292- 302 (2004). 
Stegmann T.J. et al. FGF-1: a human growth factor in the induction of neoangiogenesis. Expert 
Opinion on Investigational Drugs 7(12): 2011-2015 (1998).  
 
'*!
Stegmann T.J. et al. Induction of myocardial neoangiogenesis by human growth factors. A new 
therapeutic approach in coronary heart disease. Herz 25(6):589-599 (2000).  
Strotmann R. et al. Ca2+-dependant potentiation of the nonselective cation channel TRPV4 is 
mediated by a C-terminal Calmodulin binding site. J Biol Chem 278:26541- 26549 (2003).  
Swapnil, K.et al. Elementary Ca2+ Signals Through Endothelial TRPV4 Channels Regulate 
Vascular Function. Science 336(6081):597-601 (2012).  
Thibeault, S. L. et al. A method for identification of vocal fold lamina propria fibroblasts in 
culture. Otolaryng Head Neck 139:816-822 (2008).  
Verma, P. et al. TRPV4-mediated channelopathies. Channels 4(4):1-10 (2010). Web. 
http://www.landesbioscience.com. Retrieved 21 September 2013.  
Vriens, J. et al. Cell swelling, heat, and chemical agonists use distinct pathways for the activation 
of the cation channel TRPV4. P Natl Acad Sci USA 101:396-401 (2004).  
Woudenberg-Vrenken, T. E. et al. The role of transient receptor potential channels in kidney 
disease. Nat Rev Nephrol 5:441-449 (2009).  
World Health Organization. Global Health Estimates Summary Tables: Death by Cause, Age and 
Sex. Geneva, World Health Organization (2013). Available at 
http://www.who.int/healthinfo/mortality_data/en/. Retreived 14 October 2014.  
Zent, R. & Pozzi, A. Angiogenesis in diabetic nephropathy. Semin Nephrol 27:161-171 (2007).  
Zhou B. et al. Therapeutic Neovascularization for Peripheral Arterial Diseases: Advances and 
Perspectives. Histol Histopathol 22:677-686 (2007).  
Zhu W.H. et al. The Mouse Aorta Model: Influence of Genetic Background and Aging on bFGF- 
and VEGF-induced Angiogenic Sprouting. Angiogenesis 6:193-199 (2003).  
Zhu WH, Guo X, Villaschi S, et al. Regulation of vascular growth and regression by matrix 
metalloproteinases in the rat aorta model of angiogenesis. Lab Invest. 80:545-55 (2000). 
 
 
 
 
 
!
!!
